中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
18期
1272-1274
,共3页
曾小辉%沙卫红%李瑜元%聂玉强%黎庆宁%梁培智
曾小輝%沙衛紅%李瑜元%聶玉彊%黎慶寧%樑培智
증소휘%사위홍%리유원%섭옥강%려경저%량배지
杀伤细胞,天然%肝肿瘤%受体,NKG2D
殺傷細胞,天然%肝腫瘤%受體,NKG2D
살상세포,천연%간종류%수체,NKG2D
Killer cells,natural%Liver neoplasms%Receptor,NKG2D
目的 探讨原发性肝癌患者外周血自然杀伤(NK)细胞受体NKG2D表达的变化,并分析其对NK细胞杀伤活性的影响.方法 用流式细胞仪分析20例原发性肝癌、23例乙型肝炎后肝硬化、20例慢性乙型肝炎及20名健康者的外周血NK细胞数量及其NKG2D的表达情况,并用酶标仪检测各组样本NK细胞的细胞毒活性.结果 原发性肝癌患者的NK细胞杀伤率、NK细胞NKG2D的表达率(中位数)、NKG2D+NK细胞数(中位数)、NK细胞中NKG2D的表达水平(中位数)及NK细胞数[(25±7)%、6%、0.7×107/L、15、(1.1±0.6)×108/L]均明显低于正常组[(63±7)%、36%、8.3×107/L、116、(27±1.1)×108/L]和乙肝组[(41±8)%、16%、2.8×107/L,49、(1.9±1.1)×108/L],差异均有统计学意义(均P<0.05);与肝硬化组[(29±10)%、7%、0.6×107/L、29、(1.5±1.2)×108/L]比较也略低,但只有NK细胞NKG2D的表达水平两组差异有统计学意义(P<0.05),其余两组间差异均无统计学意义(均P>0.05).NK细胞的活性与NK细胞数、NK细胞NKG2D的表达率、NKG2D+NK细胞数、NK细胞NKG2D的表达水平均呈正相关关系(r=0.657、0.770、0.927、0.734,均P<0.01).结论 原发性肝癌患者外周血NK细胞活性及其细胞表面NKG2D的表达明显降低,NKG2D的表达与NK细胞的活性密切相关,提高NK细胞表面NKG2D的表达水平可为原发性肝癌的过继免疫治疗开创新的思路.
目的 探討原髮性肝癌患者外週血自然殺傷(NK)細胞受體NKG2D錶達的變化,併分析其對NK細胞殺傷活性的影響.方法 用流式細胞儀分析20例原髮性肝癌、23例乙型肝炎後肝硬化、20例慢性乙型肝炎及20名健康者的外週血NK細胞數量及其NKG2D的錶達情況,併用酶標儀檢測各組樣本NK細胞的細胞毒活性.結果 原髮性肝癌患者的NK細胞殺傷率、NK細胞NKG2D的錶達率(中位數)、NKG2D+NK細胞數(中位數)、NK細胞中NKG2D的錶達水平(中位數)及NK細胞數[(25±7)%、6%、0.7×107/L、15、(1.1±0.6)×108/L]均明顯低于正常組[(63±7)%、36%、8.3×107/L、116、(27±1.1)×108/L]和乙肝組[(41±8)%、16%、2.8×107/L,49、(1.9±1.1)×108/L],差異均有統計學意義(均P<0.05);與肝硬化組[(29±10)%、7%、0.6×107/L、29、(1.5±1.2)×108/L]比較也略低,但隻有NK細胞NKG2D的錶達水平兩組差異有統計學意義(P<0.05),其餘兩組間差異均無統計學意義(均P>0.05).NK細胞的活性與NK細胞數、NK細胞NKG2D的錶達率、NKG2D+NK細胞數、NK細胞NKG2D的錶達水平均呈正相關關繫(r=0.657、0.770、0.927、0.734,均P<0.01).結論 原髮性肝癌患者外週血NK細胞活性及其細胞錶麵NKG2D的錶達明顯降低,NKG2D的錶達與NK細胞的活性密切相關,提高NK細胞錶麵NKG2D的錶達水平可為原髮性肝癌的過繼免疫治療開創新的思路.
목적 탐토원발성간암환자외주혈자연살상(NK)세포수체NKG2D표체적변화,병분석기대NK세포살상활성적영향.방법 용류식세포의분석20례원발성간암、23례을형간염후간경화、20례만성을형간염급20명건강자적외주혈NK세포수량급기NKG2D적표체정황,병용매표의검측각조양본NK세포적세포독활성.결과 원발성간암환자적NK세포살상솔、NK세포NKG2D적표체솔(중위수)、NKG2D+NK세포수(중위수)、NK세포중NKG2D적표체수평(중위수)급NK세포수[(25±7)%、6%、0.7×107/L、15、(1.1±0.6)×108/L]균명현저우정상조[(63±7)%、36%、8.3×107/L、116、(27±1.1)×108/L]화을간조[(41±8)%、16%、2.8×107/L,49、(1.9±1.1)×108/L],차이균유통계학의의(균P<0.05);여간경화조[(29±10)%、7%、0.6×107/L、29、(1.5±1.2)×108/L]비교야략저,단지유NK세포NKG2D적표체수평량조차이유통계학의의(P<0.05),기여량조간차이균무통계학의의(균P>0.05).NK세포적활성여NK세포수、NK세포NKG2D적표체솔、NKG2D+NK세포수、NK세포NKG2D적표체수평균정정상관관계(r=0.657、0.770、0.927、0.734,균P<0.01).결론 원발성간암환자외주혈NK세포활성급기세포표면NKG2D적표체명현강저,NKG2D적표체여NK세포적활성밀절상관,제고NK세포표면NKG2D적표체수평가위원발성간암적과계면역치료개창신적사로.
Objective To investigate the expression of NK cells receptor NKG2D from peripheral blood in patients with primary hepatic carcinoma and the relationship between NKG2D expression and cytotoxicity of NK cells.Methods Flow cytometry was used to determine the number of NK cells and the expression of NK cells receptor NKG2D from peripheral blood in patients with primary hepatic carcinoma (20 cases) ,hepatitis B cirrhosis (23 cases ),hepatitis B ( 20 cases ) and healthy control ( 20 cases ).The microplate reader was used to detect cytotoxicity of NK cells in all cases.Results Among killing rate of NK cell for K562 cell,the expression rate of NKG2D in NK cells,the number of NKG2D+ NK cells,NKG2D expression level of NK cells and the number of NK cells,the liver cancer group[(25 ±7)% ,6% ,0.7 × 107/L,15,(1.1 ± 0.6) × 108/L]decreased significantly as compared with the healthy group [(63 ± 7 )% ,36%,8.3 ×107/L,116,(2.7 ±1.1) × 108/L]and the hepatitis B group [(41 ± 8)%,16%,2.8 × 107/L,49,(1.9 ± 1.1 ) × 108/L](P < 0.05 ) ;and there was a slight decrease as compared with the hepatitis B cirrhosis group[(29 ± 10)% ,7% ,0.6 × 107/L,29,(1.5 ± 1.2)× 108/L](all P >0.05 except NKG2D expression level of NK cells P <0.05).The activity of NK cells showed a obvious positive correlation with the number of NK cell and the positive rate of NKG2D in NK cells,the number of NKG2D+ NK cells and NKG2D expression level of NK cells (r=0.657,0.770,0.927,0.734,all P<0.01).Conclusion The cytotoxicity and the NKG2D expression of NK cells decreased significantly from peripheral blood in patients with primary hepatic carcinoma.The activity of NK cells was closely related to the NKG2D expression level of NK cells.Enhancing the NKG2D expression level of NK cell may provide a new idea for adoptive immunotherapy of primary hepatic carcinoma.